BioCryst Pharmaceuticals, Inc.
BCRX
$10.34
$0.505.08%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -977.18% | -756.52% | 396.87% | 92.91% | 75.53% |
| Total Depreciation and Amortization | 44.52% | 38.89% | 15.80% | -10.88% | 13.61% |
| Total Amortization of Deferred Charges | -64.91% | 11.76% | -- | -- | -- |
| Total Other Non-Cash Items | 543.14% | 566.32% | 12.20% | 4.02% | 3.54% |
| Change in Net Operating Assets | 10.67% | 34.42% | 34.81% | -25.25% | -23.57% |
| Cash from Operations | 2,136.64% | 1,311.06% | 767.76% | 190.08% | 120.05% |
| Capital Expenditure | -161.17% | -164.34% | -119.57% | -133.40% | 45.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -41.17% | 262.57% | -110.41% | 1,120.07% | 265.16% |
| Cash from Investing | -643.84% | -707.55% | -126.04% | 1,285.28% | 293.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -250.83% | -18,209.45% | -19,545.42% | -5,390.49% | -3,869.24% |
| Issuance of Common Stock | 267.65% | 451.96% | 126.02% | 101.14% | 118.76% |
| Repurchase of Common Stock | -87.35% | -22.00% | -9.01% | 1.71% | 3.44% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 264.19% | 1,584.03% | -5,974.14% | -2,668.00% | -1,429.71% |
| Foreign Exchange rate Adjustments | -147.68% | 615.17% | 235.68% | -95.73% | 364.73% |
| Miscellaneous Cash Flow Adjustments | 200.00% | -- | -- | -- | -- |
| Net Change in Cash | 583.73% | 220.47% | -144.71% | 75.65% | 114.38% |